ClinicalTrials.gg
CompletedNCT07750899Updated Aug 6, 2026

The Effect of Standardized Withania Somnifera Extract on Endocrine, Metabolic, and Psychometric Parameters, in Women With Polyendocrine Metabolic Ovarian Syndrome

An interventional study of Withania somnifera and Active comparator in Polyendocrine Metabolic Ovarian Syndrome, Stress and Polycystic Ovarian Syndrome (PCOS), sponsored by Medical University of Lodz. Completed at 1 site in Poland. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by Medical University of Lodz · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 5 months after the study started (first participant enrolled Jan 2025, registered Jul 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies in Polycystic Ovary Syndrome with a site in Poland — 5 open to participants now, 6 under way, none of them phase 3. Polycystic Ovary Syndrome · Poland.

Enrollment
11th of 11
28 · median 80
Started
2025
with 4 others
No phase
9 of 18
2 open now
Registered
18th of 18
by date
Lead sponsor
1 of 18
Medical University of Lodz

Among the 18 studies in Polycystic Ovary Syndrome with a site in Poland, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 with no phase, and was the 18th registered.

Polycystic Ovary Syndrome

958 studies on the registry are indexed under Polycystic Ovary Syndrome; 175 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

5 of the 18 studies in Polycystic Ovary Syndrome with a site in Poland are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 119 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 105 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Polycystic Ovary Syndrome with a site in Poland, or all of them as a file.
02

Study summary

The objective of this study is to ascertain the impact of a standardized Withania somnifera extract on endocrine, metabolic, and psychometric parameters in women diagnosed with polyendocrine metabolic ovarian syndrome. The assessment will encompass a range of parameters to determine the severity of depression, stress levels, the quality of sleep, blood pressure, body mass index, and body composition. Additionally, biochemical, metabolic, and endocrine blood parameters in serum will be analysed.

The trial's findings may yield a safe and easy-to-use method of adjunctive treatment that could complement therapy in patients with polycystic ovary syndrome.

03

Conditions studied

  • Polyendocrine Metabolic Ovarian Syndrome
  • Stress
  • Polycystic Ovarian Syndrome (PCOS)
  • Depression Symptoms
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a diagnosis confirming the presence of polycystic ovary syndrome,
  • age falling within the closed range of 18-45 years,
  • absence of pregnancy confirmed by measurement of human chorionic gonadotrophin (β-hCG) levels in serum or urine, or by a gynaecological examination,
  • not currently breastfeeding,
  • no implanted metallic devices, such as: prostheses, pacemakers, defibrillators, stents, or metallic sutures in the heart or blood vessels,
  • no diagnosed epilepsy and no history of epileptic seizures,
  • not taking anti-epileptic medication,
  • not taking benzodiazepine-based sedatives,
  • not taking medicines containing metformin (e.g. Avamina, Formetic, Glucophage, Metformax, Siofor),
  • not taking preparations containing oestrogens and/or progestogens,
  • not taking dietary supplements.

Exclusion criteria

Exclusion Criteria:

  • no diagnosis confirming the presence of polycystic ovary syndrome,
  • age under 18 or over 45,
  • pregnancy confirmed by measurement of human chorionic gonadotrophin (β-hCG) levels in serum or urine, or by a gynaecological examination,
  • currently breastfeeding,
  • having implanted metallic devices, such as: a prosthesis, a pacemaker, a defibrillator, a stent, or a metallic suture in the heart or a blood vessel,
  • diagnosed epilepsy or a history of epileptic seizures,
  • taking anti-epileptic medication,
  • taking benzodiazepine-based sedatives,
  • taking medicines containing metformin (e.g. Avamina, Formetic, Glucophage, Metformax, Siofor),
  • taking preparations containing oestrogens and/or progestogens,
  • poor general health, severe generalised and systemic diseases, including liver and kidney failure, malabsorption syndromes,
  • allergy to plants of the nightshade family,
  • taking dietary supplements.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Treatment Group

    Withania somnifera, cholecalciferol, folic acid, and 5-methyltetrahydrofolate

    Dietary Supplement: Withania somnifera

  • Active comparator
    Control group

    Cholecalciferol, folic acid, and 5-methyltetrahydrofolate

    Dietary Supplement: Active comparator

Interventions

  • Dietary supplementWithania somnifera

    Drug pages: Withanolide DStudies of Withanolide DWithanolide D pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · AshwagandhaStudies of AshwagandhaAshwagandha pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Withania somnifera (10 mg of withanolides), cholecalciferol (2000 IU), folic acid (0.4 mg), and 5-methyltetrahydrofolate (0.4 mg) orally once daily

  • Dietary supplementActive comparator

    Cholecalciferol (2000 IU), folic acid (0.4 mg), and 5-methyltetrahydrofolate (0.4 mg) orally once daily

06

What researchers measure

Primary outcomes

  1. Beck Depression Inventory (BDI-II)

    The Beck Depression Inventory (BDI-II) is a validated 21-item questionnaire assessing symptoms of depression. It includes 21 items, each containing four options, scored on a scale of 0 to 3, where 0 indicates the absence of a symptom and 3 its greatest intensity. Higher scores indicate greater symptom severity (worse outcome). This outcome measures the mean change from baseline in BDI-II total score, where a reduction in score indicates improvement in psychological symptoms.

    Time frame: Baseline, 3 months, 6 months

Secondary outcomes

  1. Perceived Stress Scale (PSS-10)

    The Perceived Stress Scale (PSS-10) is a validated 10-item self-reported questionnaire that measures perceived stress over the previous month. Each item is scored from 0 (never) to 4 (very often). The total score ranges from 0 to 40, with higher scores indicating greater perceived stress (worse outcome). This outcome measures the mean change from baseline in PSS-10 total score, where a reduction in score indicates improvement in perceived stress.

    Time frame: Baseline, 3 months, 6 months

  2. Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a validated questionnaire assessing subjective sleep quality and disturbances over the previous month. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality (worse outcome). This outcome measures the mean change from baseline in PSQI global score, where a reduction in score indicates improvement in sleep quality.

    Time frame: Baseline, 3 months, 6 months

  3. International Physical Activity Questionnaire - Short Form (IPAQ-SH)

    The IPAQ-SH (International Physical Activity Questionnaire - Short Form) is a brief, standardised tool used to assess physical activity over the last 7 days. It captures time spent in walking, moderate activity, vigorous activity, and sitting, allowing researchers to calculate weekly energy expenditure in MET-minutes.

    Time frame: Baseline, 3 months, 6 months

  4. Food Frequency Questionnaire (FFQ-6)

    The FFQ-6 (Food Frequency Questionnaire - 6-category, 62-item version) is a non-quantitative dietary assessment tool widely used in Polish nutritional research. It records the habitual frequency of consumption of 62 food items across six predefined categories, enabling the identification of dietary patterns.

    Time frame: Baseline, 3 months, 6 months

  5. Complete blood count parameters: white blood cell count (WBC), red blood cell count (RBC), haemoglobin, haematocrit, and platelets concentration

    The following parameters were analysed to evaluate changes over time within and between treatment groups.

    Time frame: Baseline, 3 months, 6 months

  6. Concentration of metabolic and inflammatory parameters: fasting glucose, fasting insulin, C-reactive protein (CRP), total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides (TG), and alanine aminotransferase (ALT) blood concentration

    The following parameters were analysed to evaluate changes over time within and between treatment groups.

    Time frame: Baseline, 3 months, 6 months

  7. Concentration of endocrine parameters: total testosterone, prolactin, oestrogen, sex hormone-binding globulin (SHBG), luteinising hormone (LH), follicle-stimulating hormone (FSH), cortisol, and dehydroepiandrosterone sulphate (DHEA-S) blood concentration

    The following parameters were analysed to evaluate changes over time within and between treatment groups.

    Time frame: Baseline, 3 months, 6 months

  8. Blood pressure parameters: systolic (SBP) and diastolic (DBP) blood pressure

    Blood pressure was measured by a sphygmomanometer.

    Time frame: Baseline, 3 months, 6 months

  9. Body composition: skeletal muscle mass, and fat mass

    The assessment of body composition was conducted through the utilisation of Bioelectrical Impedance Analysis (BIA).

    Time frame: Baseline, 3 months, 6 months

07

Study locations

1 site
  • Medical University of Lodz
    Lodz, Poland
08

References and documents

Publications

  • Zaki AA, Alharbi NM, Almundarij TI, Albarrak SM. Antioxidant and cytokine modulation in PCOS rats protected with probiotics, myo-inositol, and herbal extracts. Vet Med (Praha). 2025 Jun 27;70(6):203-217. doi: 10.17221/116/2024-VETMED. eCollection 2025 Jun. PubMed 40778261 ↗
  • Saiyed A, Jahan N, Makbul SAA, Ansari M, Bano H, Habib SH. Effect of combination of Withania somnifera Dunal and Tribulus terrestris Linn on letrozole induced polycystic ovarian syndrome in rats. Integr Med Res. 2016 Dec;5(4):293-300. doi: 10.1016/j.imr.2016.10.002. Epub 2016 Oct 19. PubMed 28462131 ↗
  • Namysl M, Matczak S, Dachowska S, Haraj J, Majcherek E, Sobkowiak M, Bieniek M, Wozniak K. Withania somnifera in Women's Hormonal Modulation: A Narrative Review With Implications for Polycystic Ovary Syndrome and Premenstrual Syndrome. Cureus. 2026 Jan 13;18(1):e101431. doi: 10.7759/cureus.101431. eCollection 2026 Jan. PubMed 41694897 ↗
  • Stanczyk K, Lopacinska O, Kedzia D, Gawlik-Kotelnicka O. Depressive and Anxiety Symptoms in Women with Polycystic Ovary Syndrome: A Meta-Analysis. J Clin Med. 2026 May 7;15(10):3582. doi: 10.3390/jcm15103582. PubMed 42194542 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Nov 2025, 10 months.

Of 204 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's 10 months is below that.

Counting every sponsor, half of 219 studies reached it within 18 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Aug 6, 2026
StartActual
Jan 16, 2025
Primary completionActual
Nov 20, 2025
CompletionActual
May 29, 2026
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07750899
Responsible party
Sponsor
First posted
Aug 6, 2026
Start date
Jan 16, 2025
Primary completion
Nov 20, 2025
Completion
May 29, 2026
Last update
Aug 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Withanolide D · Ashwagandha

Start the discussion